Samrat Pharmachem Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 553.44 million compared to INR 548.46 million a year ago. Revenue was INR 555.78 million compared to INR 549.41 million a year ago. Net income was INR 64.47 million compared to INR 15.36 million a year ago. Basic earnings per share from continuing operations was INR 20.87 compared to INR 4.97 a year ago. Diluted earnings per share from continuing operations was INR 20.87 compared to INR 4.97 a year ago.
For the nine months, sales was INR 1,616.54 million compared to INR 1,316.05 million a year ago. Revenue was INR 1,621.19 million compared to INR 1,317.47 million a year ago. Net income was INR 101.9 million compared to INR 37.73 million a year ago. Basic earnings per share from continuing operations was INR 32.98 compared to INR 12.21 a year ago. Diluted earnings per share from continuing operations was INR 32.98 compared to INR 12.21 a year ago.